VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.-45.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
VNDA vs PCRX vs SUPN vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PCRX
Pacira BioSciences, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$930M
5Y Perf.-46.2%
SUPN
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$3.01B
5Y Perf.+116.7%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
VNDA vs PCRX vs SUPN vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VNDA | PCRX | SUPN | PRGO |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $378M | $930M | $3.01B | $1.61B |
| Revenue (TTM) | $218M | $735M | $777M | $4.18B |
| Net Income (TTM) | $-240M | $9M | $-29M | $-1.82B |
| Gross Margin | 71.1% | 60.2% | 89.4% | 34.2% |
| Operating Margin | -73.6% | 3.4% | -5.5% | -4.1% |
| Forward P/E | — | 8.6x | 24.1x | 5.6x |
| Total Debt | $13M | $454M | $41M | $3.97B |
| Cash & Equiv. | $85M | $159M | $128M | $532M |
VNDA vs PCRX vs SUPN vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VNDA
PCRX
SUPN
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Vanda Pharmaceutica… (VNDA) | 100 | 54.5 | -45.5% |
| Pacira BioSciences,… (PCRX) | 100 | 53.8 | -46.2% |
| Supernus Pharmaceut… (SUPN) | 100 | 216.7 | +116.7% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VNDA vs PCRX vs SUPN vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PCRX leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. VNDA and SUPN also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
VNDA
Vanda Pharmaceuticals Inc.
The Growth Leader
VNDA is the clearest fit if your priority is growth.
- 8.7% revenue growth vs PRGO's -2.8%
Best for: growth
PCRX
Pacira BioSciences, Inc.
The Income Pick
PCRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.47
- Rev growth 3.6%, EPS growth 107.4%, 3Y rev CAGR 2.9%
- Lower volatility, beta 0.47, Low D/E 65.6%, current ratio 4.54x
- Beta 0.47, current ratio 4.54x
Best for: income & stability and growth exposure
SUPN
Supernus Pharmaceuticals, Inc.
The Long-Run Compounder
SUPN is the clearest fit if your priority is long-term compounding.
- 228.4% 10Y total return vs VNDA's -26.8%
- +69.0% vs PRGO's -51.2%
Best for: long-term compounding
PRGO
Perrigo Company plc
The Value Play
PRGO is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (5.6x vs 24.1x)
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: value and dividends
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNDA | 8.7% revenue growth vs PRGO's -2.8% |
| Value | PRGO | Lower P/E (5.6x vs 24.1x) |
| Quality / Margins | PCRX | 1.3% margin vs VNDA's -110.0% |
| Stability / Safety | PCRX | Beta 0.47 vs PRGO's 1.18, lower leverage |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | SUPN | +69.0% vs PRGO's -51.2% |
| Efficiency (ROA) | PCRX | 0.7% ROA vs VNDA's -44.6%, ROIC 2.3% vs -32.2% |
VNDA vs PCRX vs SUPN vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
VNDA vs PCRX vs SUPN vs PRGO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPCRXLAGGINGVNDA
Who Leads Where
PRGO leads in 1 of 6 categories
PCRX leads 1 • SUPN leads 1 • VNDA leads 0 • 2 tied
Explore the data ↓VNDAVanda Pharmaceuticals…
0leads
PRGOPerrigo Company plc
1leads
SUPNSupernus Pharmaceutic…
1leads
PCRXPacira BioSciences, I…
1leads
6 Total Categories
CATEGORYLEADERvs SUPNvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
PRGO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PCRX4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
SUPN6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — PCRX and SUPN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 19.2x VNDA's $218M. PCRX is the more profitable business, keeping 1.3% of every revenue dollar as net income compared to VNDA's -110.0%. On growth, SUPN holds the edge at +38.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $218M | $735M | $777M | $4.2B |
| EBITDAEarnings before interest/tax | -$150M | $95M | $29M | $58M |
| Net IncomeAfter-tax profit | -$240M | $9M | -$29M | -$1.8B |
| Free Cash FlowCash after capex | -$127M | $133M | $82M | $108M |
| Gross MarginGross profit ÷ Revenue | +71.1% | +60.2% | +89.4% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -73.6% | +3.4% | -5.5% | -4.1% |
| Net MarginNet income ÷ Revenue | -110.0% | +1.3% | -3.7% | -43.5% |
| FCF MarginFCF ÷ Revenue | -58.5% | +18.1% | +10.6% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.4% | +5.0% | +38.6% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -64.0% | -30.0% | +81.0% | -56.4% |
Evenly matched — PCRX and SUPN each lead in 3 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than SUPN's 53.4x.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Market CapShares × price | $378M | $930M | $3.0B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $305M | $1.2B | $2.9B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.71x | 147.75x | -76.88x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 8.61x | 24.12x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 9.86x | 53.44x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 1.75x | 1.28x | 4.19x | 0.38x |
| Price / BookPrice ÷ Book value/share | 1.15x | 1.54x | 2.78x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | 6.80x | 65.45x | 11.12x |
PRGO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
PCRX leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
PCRX delivers a 1.3% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-61 for VNDA. VNDA carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), PCRX scores 9/9 vs VNDA's 2/9, reflecting strong financial health.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -61.4% | +1.3% | -2.7% | -50.7% |
| ROA (TTM)Return on assets | -44.6% | +0.7% | -2.0% | -19.8% |
| ROICReturn on invested capital | -32.2% | +2.3% | -2.8% | +3.7% |
| ROCEReturn on capital employed | -33.6% | +2.8% | -3.4% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.04x | 0.66x | 0.04x | 1.35x |
| Net DebtTotal debt minus cash | -$72M | $296M | -$87M | $3.4B |
| Cash & Equiv.Liquid assets | $85M | $159M | $128M | $532M |
| Total DebtShort + long-term debt | $13M | $454M | $41M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | — | 2.37x | — | -7.20x |
PCRX leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
SUPN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SUPN five years ago would be worth $17,801 today (with dividends reinvested), compared to $3,578 for VNDA. Over the past 12 months, SUPN leads with a +69.0% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors SUPN at 12.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -22.5% | -3.4% | +5.7% | -13.5% |
| 1-Year ReturnPast 12 months | +45.9% | -6.1% | +69.0% | -51.2% |
| 3-Year ReturnCumulative with dividends | -7.8% | -44.1% | +42.1% | -58.1% |
| 5-Year ReturnCumulative with dividends | -64.2% | -62.6% | +78.0% | -60.1% |
| 10-Year ReturnCumulative with dividends | -26.8% | -51.2% | +228.4% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -2.7% | -17.6% | +12.4% | -25.2% |
SUPN leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PCRX and SUPN each lead in 1 of 2 comparable metrics.
Risk & Volatility
PCRX is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SUPN currently trades 87.6% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.47x | 0.78x | 1.18x |
| 52-Week HighHighest price in past year | $9.94 | $27.64 | $59.68 | $28.44 |
| 52-Week LowLowest price in past year | $3.81 | $18.80 | $29.16 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +64.3% | +85.5% | +87.6% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 54.9 | 45.9 | 57.9 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 695K | 604K | 3.4M |
Evenly matched — PCRX and SUPN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VNDA as "Buy", PCRX as "Hold", SUPN as "Buy", PRGO as "Hold". Consensus price targets imply 121.8% upside for VNDA (target: $14) vs 14.8% for SUPN (target: $60). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | VNDAVanda Pharmaceuti… | PCRXPacira BioScience… | SUPNSupernus Pharmace… | PRGOPerrigo Company p… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $14.17 | $29.50 | $60.00 | $20.00 |
| # AnalystsCovering analysts | 19 | 36 | 14 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | — | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +16.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRGO leads in 1 of 6 categories (Valuation Metrics). PCRX leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallPacira BioSciences, Inc. (PCRX)Leads 1 of 6 categories
Loading custom metrics...
VNDA vs PCRX vs SUPN vs PRGO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VNDA or PCRX or SUPN or PRGO a better buy right now?
For growth investors, Vanda Pharmaceuticals Inc.
(VNDA) is the stronger pick with 8. 7% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Pacira BioSciences, Inc. (PCRX) offers the better valuation at 147. 8x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Vanda Pharmaceuticals Inc. (VNDA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VNDA or PCRX or SUPN or PRGO?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VNDA or PCRX or SUPN or PRGO?
Over the past 5 years, Supernus Pharmaceuticals, Inc.
(SUPN) delivered a total return of +78. 0%, compared to -64. 2% for Vanda Pharmaceuticals Inc. (VNDA). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VNDA or PCRX or SUPN or PRGO?
By beta (market sensitivity over 5 years), Pacira BioSciences, Inc.
(PCRX) is the lower-risk stock at 0. 47β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 152% more volatile than PCRX relative to the S&P 500. On balance sheet safety, Vanda Pharmaceuticals Inc. (VNDA) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — VNDA or PCRX or SUPN or PRGO?
By revenue growth (latest reported year), Vanda Pharmaceuticals Inc.
(VNDA) is pulling ahead at 8. 7% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, PCRX leads at 2. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VNDA or PCRX or SUPN or PRGO?
Pacira BioSciences, Inc.
(PCRX) is the more profitable company, earning 1. 0% net margin versus -102. 0% for Vanda Pharmaceuticals Inc. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -70. 0% for VNDA. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VNDA or PCRX or SUPN or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 18. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VNDA: 121. 8% to $14. 17.
08Which pays a better dividend — VNDA or PCRX or SUPN or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. VNDA, PCRX, SUPN do not pay a meaningful dividend and should not be held primarily for income.
09Is VNDA or PCRX or SUPN or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Pacira BioSciences, Inc.
(PCRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (PCRX: -51. 2%, VNDA: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VNDA and PCRX and SUPN and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VNDA is a small-cap quality compounder stock; PCRX is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while VNDA, PCRX, SUPN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(VNDA: 3.4% · PCRX: 5.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.